AUTHORS
Kennedy L Watson, MD, Xu Zhang, PhD2, Victor Gordeuk, MD3, Marwah Farooqui, DO4, Franklin Njoku, MD5, Robert Molokie, MD6, Hosam Khayal, MD7, Santosh L Saraf, MD8, Zalaya Ivy, MD9
AFFILIATIONS
1 University of Illinois COM- Chicago, Chicago, United States
2 University of Illinois COM- Chicago, Chicago, United States
3 University of Illinois COM- Chicago, Chicago, United States
4 University of Illinois COM- Chicago, Chicago, United States
5 University of Illinois COM- Chicago, Chicago, United States
6 University of Illinois COM- Chicago, Chicago, United States
7 University of Illinois COM- Chicago, Chicago, United States
8 University of Illinois COM- Chicago, Chicago, United States
9 University of Illinois COM- Chicago, Chicago, United States
ABSTRACT
Background: Acute chest syndrome (ACS) is among the leading causes of morbidity and mortality in patients with sickle cell disease (SCD), yet the mechanisms underlying variability in ACS severity remain incompletely defined. Complement activation has recently been implicated in ACS pathogenesis and proposed as a therapeutic target.
We hypothesized that ACS severity in SCD is shaped by clinical phenotype and modified by genetic variation in complement and related inflammatory pathway genes. Here we describe the baseline clinical characteristics of a large, well-phenotyped SCD cohort and report preliminary candidate-gene associations with ACS occurrence and severity.
Methods: We conducted a retrospective cohort study of 440 individuals with SCD with linked clinical, laboratory, and genetic (whole genome sequencing and candidate-variant) data. ACS history was captured as a lifetime yes/no exposure; a subset with detailed prospective phenotyping (n=391) was further characterized by severity, transfusion requirement (simple vs exchange), supplemental oxygen requirement, and multi-organ failure. Single-variant association analyses assessed common variants in complement regulatory genes (CFH, CFHR2, CFHR5, CD46, MASP1, CFB) and related candidate genes (TGFBR3, SMAD1, SMAD7, NOS3, KLOTHO, HMOX1) for association with ACS occurrence, severe ACS, and an ordinal ACS severity measure (n=353 with available genotype and phenotype data).
Results: The analyzed cohort (N=391) had a mean age of 34.8 ± 12.2 years; 59.3% were female, and 96.4% identified as Black or African American. Most individuals had HbSS genotype (74.7), followed by HbSC (18.1%) and HbSβ+-thalassemia (7.2%). Hydroxyurea was used by 45% and chronic transfusion therapy by 7.4%.
Lifetime ACS history was reported in 53.9% (211/391). Among the 391 individuals with detailed ACS phenotyping, 41.9% had at least one ACS episode, 26.6% met criteria for severe ACS (ICU admission or exchange transfusion), 38.6% required any transfusion, 29.2% required high supplemental oxygen, and 13.6% developed multi-organ failure.
In candidate-gene analysis, after adjusting for age, sex, SCD genotype, and hydroxyurea use, the C allele variant in CFHR5 (rs9427662) (allele frequency = 0.39) was independently associated with ACS history (OR=0.63, p=0.004), severe ACS (OR=0.56, p=0.002), and ordinal ACS severity (OR=0.60, p<0.001; n=353). The T allele of SMAD7 (rs736839) (allele frequency = 0.18) was associated with ACS history (OR=1.9, p=0.004) and ordinal ACS severity (OR=1.6, p=0.009), though not with the severe ACS category alone (p=0.16). No other tested variants in complement or related pathway genes reached statistical significance.
Conclusions: In this large, well-characterized SCD cohort, ACS and its complications remain highly prevalent despite widespread hydroxyurea use. Preliminary candidate-gene analysis identified statistically significant associations between variants in CFHR5, a complement regulatory gene, and SMAD7, a TGF-β pathway gene, and ACS occurrence and severity. These findings support further investigation of complement and related inflammatory pathways as genetic modifiers of ACS severity and as potential therapeutic targets in SCD. Larger, replication cohorts and integrated clinical-genetic modeling are needed to confirm these associations and clarify their direction of effect.
DISCLOSURES
Kennedy L Watson, MD: No relevant conflicts of interest to declare.